The Impact of COVID-19 Disease on Platelets and Coagulation.
Pathobiology
; 88(1): 15-27, 2021.
Article
in English
| MEDLINE | ID: covidwho-858185
ABSTRACT
Coronavirus disease 2019 (COVID-19) causes a spectrum of disease; some patients develop a severe proinflammatory state which can be associated with a unique coagulopathy and procoagulant endothelial phenotype. Initially, COVID-19 infection produces a prominent elevation of fibrinogen and D-dimer/fibrin(ogen) degradation products. This is associated with systemic hypercoagulability and frequent venous thromboembolic events. The degree of D-dimer elevation positively correlates with mortality in COVID-19 patients. COVID-19 also leads to arterial thrombotic events (including strokes and ischemic limbs) as well as microvascular thrombotic disorders (as frequently documented at autopsy in the pulmonary vascular beds). COVID-19 patients often have mild thrombocytopenia and appear to have increased platelet consumption, together with a corresponding increase in platelet production. Disseminated intravascular coagulopathy (DIC) and severe bleeding events are uncommon in COVID-19 patients. Here, we review the current state of knowledge of COVID-19 and hemostasis.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Blood Coagulation Disorders
/
Blood Platelets
/
SARS-CoV-2
/
COVID-19
Type of study:
Experimental Studies
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Pathobiology
Journal subject:
Pathology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS